SPONSORSHIP ALLIANCE NEWS
Neurosciences and Spine Group in Vestal to Bring Access to State-of-the-Art Radiosurgery to Southern New York and Surrounding Communities
100 patients with wide ranging indications including multiple mets, vestibular schwannoma, meningioma, AVM, etc. Request a copy: info@zapsurgical.com.
See stunning video footage of the new ZAP-X program at Hacettepe University.
Milestone Reinforces Mutual Commitment to Advancing Healthcare Through Greater Access to State-of-the-Art Medical Technologies.
RefleXion and Limbus AI, a provider of software solutions for cancer radiation therapy, announced a technology integration agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system. This integration will reduce the most significant bottleneck in the patient treatment planning process, which involves delineating the tumor target from surrounding critical organs and other healthy tissue.
Frameless LINAC radiosurgery directed to the sensory region of selected nerve roots has been recently described as a novel treatment option to relieve severe spasticity . A prospective Sham-Controlled Trial of Dorsal Root Rhizotomy Stereotactic Radiosurgery versus Standard of Care for Spasticity Associated with Stroke, Spinal Cord Injury and Cerebral Palsy is currently underway to provide a solid assessment about the efficacy and safety of this novel treatment.
New data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois supports the use of the CyberKnife® System in treating high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of the disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to medical care teams. "Health-Related Quality of Life Following Robotic Stereotactic Body Radiation Therapy for High-Risk Prostate Cancer." [https://www.rssevents.org/fsPopup.asp?PosterID=658464&mode=posterInfo] "Acute Toxicity Following PSMA-Directed Focal Salvage Robotic SBRT for Local Recurrences Following Prior Robotic Prostate SBRT." [https://www.rssevents.org/fsPopup.asp?PosterID=658489&mode=posterInfo]
Stereotactic ablative radiotherapy (SABR) has shown benefit in early-stage non–small cell lung cancer (NSCLC) and has also shown clinical benefit in combination with immunotherapy, making it a viable treatment option to consider, according to a presentation given by Joe Y. Chang, MD, PhD, during The Radiation Oncology Summit: ACRO 2024. Chang explained that immunotherapy plus SABR could be evaluated as a curative approach.
As of January 2024, Geisinger is now equipped to conduct GammaTile Therapy procedures. “GammaTile Therapy uses radioactive cesium seeds embedded in collagen sheets to deliver safe and effective radiotherapy for patients with a wide variety of brain tumors,” said Charles T. Lee, MD, radiation oncology, Geisinger. GammaTile Therapy is best for patients with recurring tumors that have previously been treated with radiation as it allows the safe delivery of higher doses than would be allowed by traditional approaches. “The GammaTile is placed during the time of surgery and reduces the number of trips the patient needs to make to their local radiation treatment facility,” added Dr. Lee. Geisinger will continue to provide updates via the Radiosurgery Society.
Perlmutter Cancer Center at NYU - Long Island Radiation Oncology announced that it has begun enrolling and treating eligible CyberKnife patients with prostate cancer on an IRB-approved protocol that will last just two treatments rather than the usual five. They will also be integrating genomics into this particular study to intensify or deintensify the radiation based on a patient's personalized genomic pattern. Expect to hear more about this study at the free screening and education day that is being scheduled to take place in NYU's Mineola location in the spring.
The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre. Working together, MD Anderson and the IAEA aim to enhance radiation oncology, radiation physics, radiology, nuclear medicine and nutrition globally. MD Anderson operates the most comprehensive radiation oncology facility in the world and will be the first IAEA Collaborating Centre in the United States focused on health care.
As the sponsor of the SGRT Community, Vision RT is pleased to announce the full agenda for this year's annual meeting. What better way to learn how SGRT can help improve the safety, effectiveness and efficiency of your workflows than to reserve your place in the sun at this free, in-person learning event, taking place June 6-7, 2024 at the Scottsdale Plaza Resort & Villas, in Phoenix, Arizona. Our theme, 'Stay Ahead With SGRT', emphasizes the critical advantages of keeping up with the latest developments in the use of Surface Guidance - throughout the entire workflow of Sim, Plan, Treat, and Dose. SGRT has gone from "nice-to-have" to indispensable, and we'll have a full slate of expert SGRT users from some of the most prominent clinics in the world offering you their guidance and practical experience.
City of Hope has treated their first patient using SCINTIX biology-guided radiotherapy. Learn more about this exciting milestone in their recent blog.
The BIOGUIDE-X study is the newest addition to the growing body of scientific evidence supporting SCINTIX biology-guided radiotherapy. Click below to read more about this article, published in the Red Journal, which covers the clinical investigation and novel trial design that led to FDA clearance for SCINTIX therapy in primary and metastatic lung and bone tumors.
Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution. By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators. HyperSight empowers clinicians to accurately tailor treatments to each individual patient with the goal of improving patient outcomes.
RefleXion announced that the Centers for Medicare and Medicaid Services (CMS) has established a national payment rate for RefleXion’s SCINTIX® biology-guided radiotherapy using CMS’ New Technology (NT) Ambulatory Payment Classification (APC) pathway. This pathway is reserved for novel procedures that are not represented in the existing reimbursement claims data used to describe new procedures and their associated resources.
As the sponsor of the SGRT Community, Vision RT is pleased to announce that registration is open for this year's annual meeting. What better way to beat the winter doldrums than to reserve your place in the sun and join us for this free, in-person learning event, taking place June 6-7, 2024 at the Scottsdale Plaza Resort & Villas, in Phoenix, Arizona. Our theme, 'Stay Ahead With SGRT', emphasizes the critical advantages of keeping up with the latest developments in the use of Surface Guidance - throughout the entire workflow of Sim, Plan, Treat, and Dose. SGRT has gone from "nice-to-have" to indispensable, and we'll have a full slate of expert SGRT users from some of the most prominent clinics in the world offering you their guidance and practical experience.
This webinar highlights a few exciting MR-guided Radiation Therapy (MRgRT) papers from ASTRO 2023 on how MRgRT technologies, including Elekta Unity, plays a significant difference in radiation therapy around the world and the patients who need it.
Watch the replay of this webinar to learn how MRgRT is:
• Facilitating clinicians to treat with more certainty
• Improving outcomes for previously considered 'hard-to-treat' cancers
• Allowing clinicians to explore the use of MR biomarkers for dose escalation
In November and December, the radiation oncology departments at Jinan Junxin Cancer Hospital, Shanghai DeltaHealth, and Zhangpu Tianfu Hospital, all successfully delivered their first radiotherapy treatments. These departments are managed by Junxin Oncology Group to provide oncology diagnosis and treatment services. All the first treatments were offered after multiple phantom end-to-end tests, beam verifications by national/provincial calibration labs, and full-scale dry runs. All the treatment plans went through Junxin’s routine multi-disciplinary tumor board, chart rounds, and peer reviews. The offering of radiotherapy treatments will provide better treatment choices for cancer patients in more regions.
Junxin Oncology Group has always committed to research and innovation in the field of cancer treatment, enabling more medical institutions with its experience and team in cancer treatment. Junxin Oncology Group actively collaborates with cancer experts in China and internationally, introduces advanced medical technology and equipment for cancer diagnosis and treatment, and strives to provide more patients in China with high-quality and efficient treatment services.
Agreement with Mercurius Health Set to Further Expand European Presence of State-of-the-Art ZAP-X Non-Invasive Radiosurgery
Nordstrahl at the Nuremberg Nord Clinic will soon offer the latest advancement in stereotactic radiosurgery
A Phase Ib/II study by researchers from The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center, shows a combination of sensitizing drugs with a specific form of radiation therapy shows promise in improving outcomes for patients with pancreatic cancer. The approach uses a class of drugs known as superoxide dismutase mimetics to sensitize tumors to stereotactic body radiation therapy (SBRT), which allows for safer delivery of higher radiation doses. Study data, published this week in The Lancet, showed that this approach provided higher progression-free survival (PFS) and overall response rate (ORR).